Elanco

Elanco Announces the Addition of Rajeev (Bobby) Modi to Lead U.S. Pet Health

Retrieved on: 
Tuesday, February 22, 2022
Agriculture, Natural Resources, Pets, Consumer, North American Pet Health Insurance Association, Health, Conagra Brands, Growth, Animal, Interpersonal relationship, Procter & Gamble, ELAN, PETS, University, Lead, Cincinnati, Chemical engineering, NYSE, Disease, Multimedia, Enhancer (genetics), University of Cincinnati, Jerome Monroe Smucker, Veterinarian, Management, R, Component, Knowledge, History, CEO, Farmer, Bottled water, Elanco, Marketing, Food

Elanco Animal Health (NYSE: ELAN) announced today the appointment of Rajeev (Bobby) Modi as the companys executive vice president U.S. Pet Health and Global Digital Transformation.

Key Points: 
  • Elanco Animal Health (NYSE: ELAN) announced today the appointment of Rajeev (Bobby) Modi as the companys executive vice president U.S. Pet Health and Global Digital Transformation.
  • View the full release here: https://www.businesswire.com/news/home/20220222005316/en/
    Elanco welcomes Bobby Modi as executive vice president U.S. Pet Health and Global Digital Transformation.
  • Smucker, Modi led the companys pet portfolio transformation and marketing and had responsibility for the pet strategy and growth, e-commerce and innovation.
  • Watching Elanco over the years, I have been inspired by the companys deep, purpose-driven culture and energized by the robust pet health portfolio addressing some of pets greatest challenges, Modi said.

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer

Retrieved on: 
Monday, February 21, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, CureVac, Strategic planning, RNA, Information system, Hematologic Diseases Information Service, Therapy, Company, Sirna Therapeutics, Liver, KCI, Treasury, Private Securities Litigation Reform Act, RNA interference, Research, U.S. Securities and Exchange Commission, Elanco, Board, Gene, CFO, Â, BBA, Multimedia, MBA, Audit committee, Silence Therapeutics, ILEX, CEO, Chicago (franchise), AstraZeneca, Pharmacia, Sustainability Accounting Standards Board, Genzyme, Public relations, Supervisory board, Mallinckrodt, Moses Austin, University, Annual report, Industry, Upjohn, Pathology, Acquisition, Kalamazoo College, Low-density lipoprotein, SEC, Management, Accounting, Nasdaq, Silence, Finance, Economics

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Craig Tooman, previously Chief Financial Officer (CFO), has been appointed President, Chief Executive Officer (CEO) and Board member of Silence, and Mark Rothera has stepped down as President, CEO and Board member, effective immediately.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Craig Tooman, previously Chief Financial Officer (CFO), has been appointed President, Chief Executive Officer (CEO) and Board member of Silence, and Mark Rothera has stepped down as President, CEO and Board member, effective immediately.
  • Craig Tooman, President and CEO, commented, I am extremely pleased to have the opportunity to lead Silence and have come to appreciate the strong stewardship of Iain Ross as Chairman of the Board.
  • Craig Tooman joined Silence in January 2021, and brings more than 30 years of operational, financial and merger and acquisition (M&A) experience.
  • Most recently, he was Chief Operating Officer and CFO at Vyome Therapeutics, and prior to this was CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco.

BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer

Retrieved on: 
Monday, February 21, 2022
RNA transfection, Partnership, Glucose, Elanco, FSE, Neoplasm, Growth, Time, BioNTech, Annual report, Geneve L. A. Shaffer, Central tolerance, PD-1, Company, TCR, Sale, Private Securities Litigation Reform Act, Antigen, Regeneron Pharmaceuticals, BNTX, PD-L1, Biotechnology, Infection, Cancer, Nasdaq, ISIN, Patient, Hoffmann-La Roche, EUR, Immunotherapy, Research, PRAME, Program, SEC, Vaccine, Pharmaceutical industry, Pfizer, Genentech, MediGene

Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech.

Key Points: 
  • Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech.
  • Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene: Medigene is at the forefront of the development of TCR-T therapies for oncology.
  • This has the potential to augment TCR cell therapy efficacy and can be applied to all BioNTech cell therapy programs.
  • BioNTech will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR therapies resulting from this research collaboration.

Elanco to Participate in the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 21, 2022
Veterinary, Pets, Specialty, Food, Beverage, Health, Consumer, Retail, Agriculture, Natural Resources, ELAN, Conference, PETS, Health, Farmer, Veterinarian, Elanco, CEO, Animal, Interpersonal relationship, NYSE, Disease, Veterinary medicine, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022.
  • Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:50 p.m.
  • With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities.
  • At Elanco, were driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose CSR framework all to advance the health of animals, people and the planet.

Insights on the Animal Vaccines Global Market to 2030: Recombinant Vaccine is Expected to Witness Considerable Growth During Forecast Period - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Veterinary, Health, Route of administration, Health, Incidence, Prevalence, Human, Food and Drug Administration, Animal, Vaccine, Ruminant, CPV, Awareness, Therapy, Livestock, Oral and maxillofacial pathology, Cattle, CZ, Tuberculosis, USD, Brucellosis, Elanco, Companion, Growth, Ceva, CAGR, Anisakis, Investment, Foot, Reed Elsevier, Inc. v. Muchnick, Agriculture

The global animal vaccines market size is expected to reach USD 26.12 billion by 2030.

Key Points: 
  • The global animal vaccines market size is expected to reach USD 26.12 billion by 2030.
  • The growing incidence of food-borne zoonotic diseases and increasing animal husbandry are boosting the demand for vaccines.
  • The recombinant vaccine is expected to witness considerable growth during the forecast period.
  • For instance, in October 2021, CZ VACCINES launched a new conjunctival vaccine called B19 CZV Ocular, thus adding a new vaccine to its range of brucellosis vaccines

Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors

Retrieved on: 
Friday, February 18, 2022
NYSE, Patient, AAV, Time, CEO, PETS, Science, ELAN, Lilly, Company, Champaign County, Illinois, Animal, R, Eli Lilly and Company, Board of directors, Novartis, Boehringer Ingelheim, Biotechnology, Therapy, Board, Schacht, Research, University, GLOBE, Fine chemical, Management, Elanco

PHILADELPHIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Scout Bio , a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors.

Key Points: 
  • PHILADELPHIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Scout Bio , a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors.
  • Mr. Schacht is a deeply experienced life sciences executive with management expertise across a wide range of functions and will work with Scout Bio to execute its strategic development as a veterinary biopharma pioneer.
  • I look forward to working with the entire Scout Bio team to support the advancement of the companys business and rich pipeline.
  • I am pleased to welcome Aaron to Scout Bio during an exciting period where his expertise will add significant value to our corporate strategy, said Mark Heffernan, Ph.D., chief executive officer of Scout Bio.

BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa

Retrieved on: 
Tuesday, February 15, 2022
CET, Cancer, Geneve 9640, Company, Regeneron Pharmaceuticals, Flávio Kenup, Immunotherapy, Elanco, BioNTech, RNA transfection, International, Infection, Nasdaq, African Union, BNTX, Hoffmann-La Roche, Pharmaceutical industry, Genentech, Union, African, Pfizer

MAINZ, Germany, February 15, 2022 BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on sustainable vaccine manufacturing in the African Union.

Key Points: 
  • MAINZ, Germany, February 15, 2022 BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on sustainable vaccine manufacturing in the African Union.
  • The meeting initiated by the kENUP foundation will be followed by public statements on February 16, 2022 at approx.
  • President Macky Sall of Senegal, President of the African Union
    The statements can be accessed via live-stream and broadcast usage here: Link
    Following the public statements, BioNTech will hold a digital press conference to provide an update on its vaccine manufacturing efforts on the African continent.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age

Retrieved on: 
Friday, February 11, 2022
Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Pfizer–BioNTech COVID-19 vaccine, Emergency Use Authorization, Cancer, EUA, Risk, Pierre Geneves, Company, Science, News, YouTube, Regeneron Pharmaceuticals, SEC, Immunotherapy, Facebook, Elanco, BioNTech, Vaccine, RNA transfection, Private Securities Litigation Reform Act, Infection, Awareness, Clinical trial, Safety, Annual report, Hoffmann-La Roche, LinkedIn, Pediatrics, U.S. Securities and Exchange Commission, Twitter, Publication, Marketing, Peer review, Research, BNT162, COVID-19, Program, Pharmaceutical industry, Genentech, Pfizer, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

For more than 170 years, we have worked to make a difference for all who rely on us.

Key Points: 
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.Pfizer.com .
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Elanco Adds New Tools to Advance U.S. Livestock Sustainability Efforts

Retrieved on: 
Monday, February 7, 2022
Pets, Technology, Public Policy, Government, Veterinary, Fitness & Nutrition, Consumer, Agriculture, Natural Resources, Health, Alternative Energy, Energy, Food, Beverage, White House, Federal Government, Software, Retail, Environment, Data Management, Zero, Narrative, Knowledge, ELAN, Obesity, Industry, Duck, Statistics, Proposition, Interpersonal relationship, Simmons, Ducks Unlimited, Elanco, Food chain, Gene, World, Program, Analytics, U.S. Department of Defense Strategy for Operating in Cyberspace, Livestock, Veterinarian, Malnutrition, NYSE, Population, PETS, CEO, Adoption, Farmer, Health, Animal, Climate change, Aircraft, GHG, National, EKS, Carbon footprint, United Nations, Hunger, Carbon, Disease, Partnership, World Health Organization, Education, Certification, First Nations in Ontario, Agriculture, Renewable energy, Food

We believe environmental sustainability is the next era of opportunity for livestock production, said Jeff Simmons, president and CEO of Elanco Animal Health.

Key Points: 
  • We believe environmental sustainability is the next era of opportunity for livestock production, said Jeff Simmons, president and CEO of Elanco Animal Health.
  • Elanco is piloting UpLook, an insights engine based on more than 20 years of knowledge gained from its Elanco Knowledge Solutions (EKS) portfolio.
  • We are excited to start to turn our commitments into action, said Dr. Sara Place, chief sustainability officer at Elanco.
  • Athians Sustainable Livestock Systems platform is an industry-based analytics tool powered by AI that enables the livestock industry to make good on its sustainability commitments by providing carbon insetting credits.

Elanco to Participate in the BofA Securities 2022 Virtual Animal Health Summit

Retrieved on: 
Friday, February 4, 2022
Other Health, Other Retail, Specialty, Consumer, Agriculture, Natural Resources, Food, Beverage, Retail, Other Consumer, Veterinary, Health, Pets, Home Goods, ELAN, CEO, Interpersonal relationship, Disease, Animal, PETS, Farmer, Elanco, Health, Bank of America, NYSE, Veterinarian, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on Thursday, February 24, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on Thursday, February 24, 2022.
  • Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:35 p.m.
  • Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole.
  • At Elanco, were driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose CSR framework all to advance the health of animals, people and the planet.